New Oral Treatments

New oral treatment options have emerged with a sophisticated approach to treating psoriatic arthritis. These so-called “small-molecule” treatments can be delivered effectively by mouth. Unlike earlier oral DMARDs for psoriatic arthritis, these new oral treatments selectively target molecules inside immune cells. By adjusting the complicated processes of inflammation within the cell, these treatments correct the overactive immune response that causes inflammation in people with psoriatic arthritis, leading to improvement in joint tenderness and swelling.


The newest available oral treatment for psoriatic arthritis is Otezla (apremilast). Otezla treats psoriatic arthritis by regulating inflammation within the cell. It inhibits an enzyme known as phosphodiesterase 4, or PDE4. PDE4 controls much of the inflammatory action within cells, which can affect the level of inflammation associated with psoriatic arthritis.

By helping to control inflammation in this way, Otezla improves joint tenderness and swelling in people with active psoriatic arthritis.

Otezla is available as a 30-milligram (mg) tablet. The first five days is a start period, where the dosage will gradually increase over five days until the recommended dose of 30 milligrams twice daily is reached. Otezla is designed to be taken continuously to maintain improvement.

Get more information: